Fortis Malar Hospitals Ltd vs Transgene Biotek Ltd Stock Comparison
Fortis Malar Hospitals Ltd vs Transgene Biotek Ltd Stock Comparison
Last Updated on: Oct 26, 2026
Key Highlights
The Latest Trading Price of Fortis Malar Hospitals Ltd is ₹ 39.88 as of 26 Oct 15:30
. The P/E Ratio of Fortis Malar Hospitals Ltd changed from 1.9 on March 2024 to 18.9 on March 2026 . This represents a CAGR of 115.06% over 3 yearsThe P/E Ratio of Transgene Biotek Ltd changed from 0 on March 2021 to 0 on March 2026 . This represents a CAGR of 0.0% over 6 years The Market Cap of Fortis Malar Hospitals Ltd changed from ₹ 103.92 crore on March 2021 to ₹ 78.13 crore on March 2026 . This represents a CAGR of -4.64% over 6 yearsThe Market Cap of Transgene Biotek Ltd changed from ₹ 34.7 crore on March 2021 to ₹ 0 crore on March 2026 . This represents a CAGR of -100.00% over 6 years The revenue of Fortis Malar Hospitals Ltd for the Jun '26 is ₹ 0.54 crore as compare to the Mar '26 revenue of ₹ 0.66 crore. This represent the decline of -18.18% The revenue of Transgene Biotek Ltd for the Jun '26 is ₹ 0.06 crore as compare to the Mar '26 revenue of ₹ 0.2 crore. This represent the decline of -70% The ebitda of Fortis Malar Hospitals Ltd for the Jun '26 is ₹ 0.2 crore as compare to the Mar '26 ebitda of ₹ 0.11 crore. This represent the growth of 81.82% The ebitda of Transgene Biotek Ltd for the Jun '26 is ₹ -0.06 crore as compare to the Mar '26 ebitda of ₹ -0.13 crore. This represent the decline of -53.85% The net profit of Fortis Malar Hospitals Ltd changed from ₹ -0.06 crore to ₹ 0.15 crore over 9 quarters. This represents a CAGR of NaN%
The net profit of Transgene Biotek Ltd changed from ₹ 0.2 crore to ₹ -0.39 crore over 9 quarters. This represents a CAGR of NaN%
The Dividend Payout of Fortis Malar Hospitals Ltd changed from 168.63 % on March 2024 to 0 % on March 2026 . This represents a CAGR of -100.00% over 3 yearsThe Dividend Payout of Transgene Biotek Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 years .
About Fortis Malar Hospitals Ltd
Fortis Malar Hospital Limited, formerly known as Malar Hospital Limited was established on April 12, 1989 to set up, manage and operate a multi-specialty hospital.
Company is a subsidiary of Fortis Hospitals Limited and Fortis Healthcare Limited is the Intermediate Holding Company.
Later, the Company changed its name to 'Fortis Malar Hospital Limited' on December 21, 2010.
The Hospital building was owned by a fellow subsidiary, Fortis Health Management Limited (FHML) in early 2008.
The hospital founded in 1989, has established itself as one of the largest corporate hospitals in Chennai, providing quality super specialty and multi-speciality healthcare services.
With a total bed-strength of 160, including 40 ICU/CCU/RTU beds, the hospital focuses on providing comprehensive medical care in the areas of Cardiology and Cardiac Surgery, Neuro Surgery, Gynaecology, Orthopedics, Gastroenterology, Neurology, Pediatrics, Diabetics, Nephrology and Internal Medicine
All the above departments are fully became operational under phase I of the project.
About Transgene Biotek Ltd
Founded in March 1990 by Dr. Koteswara Rao, Transgene Biotek Limited was one of the first Biotechnology companies in India.
Although Transgene began life manufacturing and selling diagnostic kits, it soon moved on to true biotech research, including the research and development of vaccines, oncology , New drug delivery technologies etc.
The first major success came when it sold genetically engineered recombinant Hepatitis B vaccine technology along with novel and patented process in 1999 to the Serum Institute, Pune.
Presently, the Company is engaged in the business of research and development and manufacture of various medical reagents, both chemical and immuno-diagnostic reagents for qualitative and quantitative estimation of bio-chemical parameters and diagnosis of diseases respectively.
FAQs for the comparison of Fortis Malar Hospitals Ltd and Transgene Biotek Ltd
Which company has a larger market capitalization, Fortis Malar Hospitals Ltd or Transgene Biotek Ltd?
Market cap of Fortis Malar Hospitals Ltd is 75 Cr while Market cap of Transgene Biotek Ltd is 19 Cr
What are the key factors driving the stock performance of Fortis Malar Hospitals Ltd and Transgene Biotek Ltd?
The stock performance of Fortis Malar Hospitals Ltd and Transgene Biotek Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.
What are the recent stock price for Fortis Malar Hospitals Ltd and Transgene Biotek Ltd?
As of October 26, 2026, the Fortis Malar Hospitals Ltd stock price is INR ₹40.21. On the other hand, Transgene Biotek Ltd stock price is INR ₹2.57.
How do dividend payouts of Fortis Malar Hospitals Ltd and Transgene Biotek Ltd compare?
To compare the dividend payouts of Fortis Malar Hospitals Ltd and Transgene Biotek Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.